Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 10 04:00PM ET
1.90
Dollar change
-0.03
Percentage change
-1.55
%
Index- P/E- EPS (ttm)-1.06 Insider Own32.42% Shs Outstand29.81M Perf Week-3.06%
Market Cap109.11M Forward P/E- EPS next Y-0.98 Insider Trans-17.02% Shs Float22.51M Perf Month-21.16%
Income-28.17M PEG- EPS next Q-0.26 Inst Own14.32% Short Float7.09% Perf Quarter-22.76%
Sales0.00M P/S- EPS this Y10.61% Inst Trans104.94% Short Ratio0.90 Perf Half Y-52.62%
Book/sh0.10 P/B18.15 EPS next Y17.48% ROA-49.43% Short Interest1.60M Perf Year-39.49%
Cash/sh0.54 P/C3.53 EPS next 5Y-9.40% ROE-272.52% 52W Range1.85 - 8.75 Perf YTD-42.77%
Dividend Est.- P/FCF- EPS past 5Y0.28% ROI-136.25% 52W High-78.29% Beta0.05
Dividend TTM- Quick Ratio1.60 Sales past 5Y83.82% Gross Margin- 52W Low2.70% ATR (14)0.14
Dividend Ex-Date- Current Ratio1.60 EPS Y/Y TTM25.22% Oper. Margin- RSI (14)37.84 Volatility4.91% 5.79%
Employees140 Debt/Eq10.81 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price11.75
Option/ShortYes / Yes LT Debt/Eq5.62 EPS Q/Q34.65% Payout- Rel Volume0.22 Prev Close1.93
Sales Surprise- EPS Surprise17.24% Sales Q/Q- EarningsNov 14 BMO Avg Volume1.77M Price1.90
SMA20-8.38% SMA50-16.38% SMA200-45.90% Trades Volume380,514 Change-1.55%
Date Action Analyst Rating Change Price Target Change
Aug-02-24Initiated Oppenheimer Outperform $17
Jun-14-24Initiated Maxim Group Buy $15
Jun-13-24Initiated Rodman & Renshaw Buy $10
Apr-17-23Resumed BTIG Research Buy $24
Oct-11-22Initiated UBS Buy $15
Jul-27-22Initiated H.C. Wainwright Buy $22
Jun-13-22Initiated Wedbush Outperform $28
Nov-14-24 08:00AM
Nov-07-24 04:05PM
Oct-17-24 08:00AM
Oct-15-24 08:30AM
Oct-13-24 06:01AM
04:05PM Loading…
Oct-08-24 04:05PM
Sep-03-24 04:05PM
Aug-06-24 04:05PM
Jul-29-24 04:05PM
Jul-22-24 08:30AM
Jun-24-24 07:00AM
May-16-24 10:15AM
May-14-24 08:00AM
May-09-24 08:00AM
May-07-24 09:06PM
09:55PM Loading…
May-06-24 09:55PM
04:05PM
Mar-21-24 09:45AM
06:35AM
Mar-20-24 04:05PM
Mar-15-24 04:05PM
Feb-05-24 08:00AM
Dec-14-23 08:00AM
Dec-07-23 12:00PM
Nov-08-23 05:53PM
04:05PM
Nov-01-23 04:05PM
Oct-25-23 08:00AM
Oct-19-23 04:05PM
Oct-12-23 04:05PM
08:00AM Loading…
Sep-18-23 08:00AM
Sep-07-23 04:05PM
Sep-06-23 08:00AM
Aug-11-23 04:05PM
Aug-04-23 04:05PM
Jun-21-23 08:00AM
Jun-08-23 08:00AM
Jun-05-23 08:00AM
Jun-01-23 08:00AM
May-31-23 08:00AM
May-24-23 08:00AM
May-17-23 09:50AM
May-10-23 04:05PM
Apr-26-23 06:46AM
Apr-25-23 08:00AM
Apr-11-23 08:00AM
Mar-27-23 07:12AM
Mar-22-23 04:05PM
Mar-16-23 04:05PM
Jan-09-23 08:30AM
Jan-05-23 04:05PM
Dec-06-22 04:05PM
Nov-17-22 05:30AM
Nov-10-22 05:25PM
04:05PM
Nov-09-22 04:05PM
Oct-28-22 09:55AM
Oct-24-22 08:30AM
Sep-27-22 09:06AM
Sep-06-22 04:05PM
Aug-11-22 11:47PM
Aug-10-22 05:45PM
05:28PM
04:28PM
04:23PM
Aug-08-22 08:30AM
Aug-03-22 07:48AM
May-11-22 04:05PM
May-04-22 03:09PM
May-03-22 04:05PM
07:00AM
Apr-07-22 04:05PM
Mar-29-22 04:05PM
Mar-23-22 08:38PM
08:00AM
Feb-23-22 08:00AM
Jan-19-22 04:30AM
Jan-07-22 08:00AM
Dec-20-21 07:26PM
Nov-15-21 07:31PM
Nov-12-21 04:05PM
Nov-10-21 04:05PM
Oct-08-21 12:42PM
Oct-04-21 06:00AM
Sep-23-21 04:05PM
Sep-13-21 04:05PM
Sep-09-21 08:00AM
Aug-24-21 02:14PM
Aug-13-21 04:05PM
Jul-30-21 08:56AM
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Imran TalatChief Executive OfficerDec 09 '24Buy1.9410,29619,974494,751Dec 10 01:12 PM
South Cone Investments Limited10% OwnerOct 15 '24Sale2.653,829,36010,141,6748,302,194Oct 17 04:30 PM